Last reviewed · How we verify

NCT04474327

Role of Montelukast in Modulation of Response to Sepsis in Preterm Infants

Completed Phase 1 Last updated 11 February 2021
What this trial tests

Phase 1 trial testing Montelukast Sodium in Neonatal Sepsis in 40 participants. Completed in 10 February 2021.

Timeline
24 July 2020
Primary endpoint
10 February 2021
10 February 2021

Quick facts

Lead sponsorMansoura University Children Hospital
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment40
Start date24 July 2020
Primary completion10 February 2021
Estimated completion10 February 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Mansoura University Children Hospital

Who can join

Adults 1 Day to 30 Days, any sex, with Neonatal Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will conduct this study to explore the role of Montelukast in treatment of neonatal sepsis and whether it has an effect on inflammatory markers, the duration of antibiotic use, or on the patients´ outcome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Montelukast Sodium

Trials testing the same drug.

Other recruiting trials for Neonatal Sepsis

Currently open trials in the same condition.

Other Mansoura University Children Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04474327.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing